{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:42:01Z","timestamp":1783539721404,"version":"3.55.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,15]]},"DOI":"10.1093\/ibd\/izy133","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T14:05:02Z","timestamp":1524751502000},"page":"2272-2277","source":"Crossref","is-referenced-by-count":20,"title":["Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy"],"prefix":"10.1093","volume":"24","author":[{"given":"Guilherme P","family":"Ramos","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Stroh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"Faubion","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos A","family":"Papadakis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Escalante","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic Center of Tuberculosis, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"key\n\t\t\t\t20180915041323_CIT0001","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180915041323_CIT0002","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: american college of gastroenterology, practice parameters committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180915041323_CIT0003","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.21382","article-title":"Tuberculosis associated with therapy against tumor necrosis factor alpha","volume":"52","author":"Winthrop","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180915041323_CIT0004","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180915041323_CIT0005","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180915041323_CIT0006","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1086\/429998","article-title":"Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept","volume":"41","author":"Ehlers","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0007","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180915041323_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04146.x","article-title":"How tumour necrosis factor blockers interfere with tuberculosis immunity","volume":"161","author":"Harris","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20180915041323_CIT0009","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/apt.13215","article-title":"Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease","volume":"41","author":"Luthra","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180915041323_CIT0010","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cgh.2007.04.007","article-title":"Risk for active tuberculosis in inflammatory bowel disease patients","volume":"5","author":"Aberra","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180915041323_CIT0011","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.3748\/wjg.v21.i11.3308","article-title":"Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents","volume":"21","author":"Kim","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20180915041323_CIT0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3346\/jkms.2015.30.2.173","article-title":"The risk of tuberculosis in korean patients with inflammatory bowel disease receiving tumor necrosis factor-\u03b1 blockers","volume":"30","author":"Byun","year":"2015","journal-title":"J Korean Med Sci"},{"key":"key\n\t\t\t\t20180915041323_CIT0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/rheumatology\/keh464","article-title":"Update on the British society for rheumatology guidelines for prescribing tnfalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)","volume":"44","author":"Ledingham","year":"2005","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180915041323_CIT0014","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180915041323_CIT0015","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180915041323_CIT0016","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection: United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180915041323_CIT0017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American thoracic society\/infectious diseases society of America\/centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0018","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Cohn DL, O\u2019Brien RJ, Geiter LJ, et al. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180915041323_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041323_CIT0020","article-title":"Diagnosis and management of tuberculosis in candidates for tumor necrosis factor alpha antagonists: an experts survey","volume":"4","author":"Birkenkamp","year":"2014","journal-title":"Mycobacterial Diseases"},{"key":"key\n\t\t\t\t20180915041323_CIT0021","first-page":"C4480","article-title":"Guidelines for screening, prophylaxis and critical information before initiating anti-TNF-alpha treatment","volume":"59","author":"Nordgaard-Lassen","year":"2012","journal-title":"Dan Med J"},{"key":"key\n\t\t\t\t20180915041323_CIT0022","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn\u2019s disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180915041323_CIT0023","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1513\/AnnalsATS.201701-055ED","article-title":"Minimizing tuberculosis risk in patients receiving anti-TNF therapy","volume":"14","author":"Esmail","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"key\n\t\t\t\t20180915041323_CIT0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2007.03553.x","article-title":"Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease","volume":"27","author":"Theis","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180915041323_CIT0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MIB.0000000000001003","article-title":"Tuberculosis screening and reactivation among a national cohort of patients with inflammatory bowel disease treated with tumor necrosis factor alpha antagonists","volume":"23","author":"Hou","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0026","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0027","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening","volume":"7","author":"Jauregui-Amezaga","year":"2013","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180915041323_CIT0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo Clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180915041323_CIT0029","first-page":"498","article-title":"Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results","volume":"12","author":"Menzies","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Estimated rate of reactivation of latent tuberculosis infection in the united states, overall and by population subgroup","volume":"179","author":"Shea","year":"2014","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20180915041323_CIT0031","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180915041323_CIT0032","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180915041323_CIT0033","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key\n\t\t\t\t20180915041323_CIT0034","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180915041323_CIT0035","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcp021045","article-title":"Clinical practice. Latent tuberculosis infection","volume":"347","author":"Jasmer","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180915041323_CIT0036","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0037","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"Lobue","year":"2010","journal-title":"Respirology"},{"key":"key\n\t\t\t\t20180915041323_CIT0038","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41598-017-06899-1","article-title":"Active tuberculosis incidence and characteristics in patients treated with tumor necrosis factor antagonists according to latent tuberculosis infection","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20180915041323_CIT0039","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/00365521.2014.1000960","article-title":"Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-\u03b1 inhibitor","volume":"50","author":"Byun","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20180915041323_CIT0040","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ibd.20496","article-title":"Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients before anti-TNF therapy","volume":"14","author":"Zabana","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0041","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1513\/AnnalsATS.201608-647OC","article-title":"Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist","volume":"14","author":"Lee","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"key\n\t\t\t\t20180915041323_CIT0042","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1399-0039.2007.00843.x","article-title":"Macrophage migration inhibitory factor gene influences the risk of developing tuberculosis in northwestern colombian population","volume":"70","author":"G\u00f3mez","year":"2007","journal-title":"Tissue Antigens"},{"key":"key\n\t\t\t\t20180915041323_CIT0043","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/ajg.2013.144","article-title":"Reactivation of latent tuberculosis in a Crohn\u2019s patient after TB prophylaxis treated with adalimumab","volume":"108","author":"Caldera","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180915041323_CIT0044","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/apt.12037","article-title":"Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-\u03b1 inhibitors","volume":"36","author":"Papay","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180915041323_CIT0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2006.02786.x","article-title":"Review article: infliximab therapy for inflammatory bowel disease\u2013seven years on","volume":"23","author":"Rutgeerts","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180915041323_CIT0046","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.201412-2141OC","article-title":"Combinatorial immunoprofiling in latent tuberculosis infection. Toward better risk stratification","volume":"192","author":"Escalante","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180915041323_CIT0047","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00408-014-9655-9","article-title":"Diagnosis of latent tuberculosis infection with T-SPOT(\u00ae).TB in a predominantly immigrant population with rheumatologic disorders","volume":"193","author":"Escalante","year":"2015","journal-title":"Lung"},{"key":"key\n\t\t\t\t20180915041323_CIT0048","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180915041323_CIT0049","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/01.MIB.0000438429.38423.62","article-title":"T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease","volume":"20","author":"Arias-Guill\u00e9n","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0050","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2012-201979","article-title":"You can\u2019t always get what you want, but if you try sometimes (with two tests\u2013TST and IGRA\u2013for tuberculosis) you get what you need","volume":"71","author":"Winthrop","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0051","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/ibd.22901","article-title":"Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Shahidi","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180915041323_CIT0052","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/rccm.201506-1119ED","article-title":"First steps in biomarker assessment for reactivation risk in latent tuberculosis infection","volume":"192","author":"Gleeson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180915041323_CIT0053","author":"CDC","year":"2018"},{"key":"key\n\t\t\t\t20180915041323_CIT0054","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","article-title":"Influence of replacing tuberculin skin test with ex vivo interferon \u03b3 release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy","volume":"71","author":"Mariette","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/10\/2272\/25739039\/izy133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T02:35:32Z","timestamp":1661049332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/10\/2272\/4987150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,4,26]]},"published-print":{"date-parts":[[2018,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy133","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,4,26]]}}}